US4837018A - Vaccines for fowl colibacillosis - Google Patents
Vaccines for fowl colibacillosis Download PDFInfo
- Publication number
- US4837018A US4837018A US07/079,803 US7980387A US4837018A US 4837018 A US4837018 A US 4837018A US 7980387 A US7980387 A US 7980387A US 4837018 A US4837018 A US 4837018A
- Authority
- US
- United States
- Prior art keywords
- vaccine
- poultry
- colibacillosis
- inactivated
- vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 46
- 244000144977 poultry Species 0.000 claims abstract description 24
- 241000588724 Escherichia coli Species 0.000 claims abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 10
- 210000003555 cloaca Anatomy 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 235000013594 poultry meat Nutrition 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- -1 aluminum compound Chemical class 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
Definitions
- This invention relates to a vaccine useful for the protection of poultry from colibacillosis infections. More specifically, this invention relates to a vaccine which comprises as an active ingredient ultrasonically disintegrated cells of Escherichia coli which have been pre-inactivated. This invention also relates to a method for protecting poultry from colibacillosis infections which comprises inoculating the vaccine of the invention into the poultry through cloaca.
- “Fowl colibacillosis” includes various diseases in poultry caused by pathogenic E. coli strains (colibacillus), such as colisepsis, arrthritis, hemorrhagic enterisis, and the like. Mass outbreak of colisepsis in broilers, among others, brings serious economical damage to farmers. Accordingly, development of any efficient method for the treatment and prophylaxis of the fowl colibacillosis has long been a major problem to poultry farmers.
- this invention provides a vaccine useful for the protection of poultry from colibacillosis infections which comprises E. coli cells which have been pre-inactivated and ultrasonicated.
- This invention also provides a method for protecting poultry from colibacillosis infections by inoculating the vaccine into poultry through cloaca.
- pre-inactivated E. coli cells means E. coli cells which have been inactivated in usual ways.
- Pre-inactivated and ultrasonicated E. coli cells refers to E. coli cells which have been subjected to an inactivating process and then to an ultrasonic disruption process.
- Panttry refers to domestic fowls such as chickens, ducks, quails, pigeons, turkeys, and the like.
- Pathogenic E. coli cells are isolated from organs (e.g. air sac) or droppings of poultry suffering from colibacillosis and grown in a culture medium by conventional methods.
- the resulting cell culture is treated by an inactivating agent such as formalin (a 40% aqueous formaldehyde solution), phenol, acetone, alcohols, and the like.
- formalin a 40% aqueous formaldehyde solution
- phenol phenol
- acetone acetone
- alcohols and the like.
- any other known inactivating methods for example, lyophilisation and heat treatment can also be used.
- the inactivated cell culture prepared above is subjected to an ultrasonic disruption treatment using any commercially available apparatus (e.g. Cell Disruper 200, BRANSON) under appropriate conditions. Suitable conditions for the disruption treatment may vary depending on the particular apparatus and other factors. When Cell Disruper 200 is employed, the ultrasonic disruption may be conducted under the following conditions: maximum output, 50% oscillation frequency, for 5 minutes, three times, with cooling on ice. Any other ultrasonicating apparatus can be used for preparing the vaccine of the invention, provided that such apparatus can successfully injure and destroy E. coli cells.
- the inactivated cell culture may be first centrifuged to collect the cells, which are then suspended in PBS to prepare a bacterial solution. The resulting bacterial solution is then subjected to the ultrasonic disruption treatment as mentioned above.
- a process for the preparation of vaccines which contain inactivated bacteria cells as an active ingredient is well known to the art.
- the vaccine of the present invention which contains pre-inactivated and ultrasonicated E. coli cells can be prepared in the same manner as the known vaccines.
- the vaccine of the invention may contain an adjuvant, for example, an aluminum compound such as aluminium hydroxide gel, or Freund's complete adjuvant.
- the vaccine of the invention may also contain a preservative for prevention of the growth of undesirable microorganisms.
- Preferred preservatives are, for example, marzonine, tyrosine, benzoic acid, formaldehyde solution, salicylic acid, crystal violet, surfactants such as benzetonium chloride, polymyxin, gramicidine, and the like.
- the vaccine of the invention can be conventionally administered, for example, intramuscularly, intravenously, or subcutaneously.
- administration routes may sometimes cause weight loss of poultry as in the case of known vaccines.
- disadvantageous effect can be reduced or diminished by inoculating the vaccine through cloaca as stated before.
- 0.002-0.2mil (about 2 ⁇ 10 5 -2 ⁇ 10 10 CFU/ml) of vaccine of the invention is inoculated through cloaca into each poultry such as chicken, duck, or turkey.
- Such doses are sufficient to protect the poultry from colibacillosis and to prevent mass infections of said disease.
- Pathogenic E. coli strains isolated from air sacs of chickens suffering from colibacillosis were incubated in a broth medium at 37° C. for about 24 hours. To the cell culture was added formalin to a final concentration of 0.2%. The inactivated cell culture thus obtained contained more than 1.5 ⁇ 10 9 cells per ml (CFU/ml). A portion of the cell culture was ultrasonicated using Cell Disruper 200 (BRANSON) at 50% oscillation frequency under maximum output (5 minutes, 3 times) with cooling on ice. This gave vaccine (1) of the invention.
- BRANSON Cell Disruper 200
- Inactivated cells were collected by centrifugation (14000 ⁇ G for 20 minutes at 4° C.), and then suspended into PBS to prepare a bacterial solution which contained inactivated E. coli cells at a density of 2 ⁇ 10 10 CFU/ml. The bacterial solution was then applied to the aforementioned Cell Disruper to yield vaccine (2) of the invention.
- the PBS solution was prepared as follows: 11.9g of NaH 2 P 4 12H 2 O, 3.6g of NaH 2 PO 4 2H 2 O, and 0.6g of NaC1 were throughly admixed. To the mixture was added distilled water to a final volume of 1 liter, and the resultant solution was sterilized before use.
- the vaccines prepared above were inoculated into poultries, and the immunization activity thereof was evaluated as descried below.
- Pathogenic E. coli solution and its inactivated solution prepared in Examples (1,1) and (1,2) were used as positive control vaccine (1) and positive control vaccine (2) respectively. Eleven chicks (Chankey, broiler species) within 30 hours after hatching were used for tests. Each chick was inoculated with 0.03ml of vaccine (1), vaccine (2), positive control vaccine (1) or positive control vaccine (2) through cloaca by intravenous drip method (see Japanese Patent Publication (unexamined) No. 131920/1983). When the chick become 21-days-old, 6 ⁇ 10 7 CFU of pathogenic E. coli cells, the same strain as used in the preparation of the vaccines, were intravenously injected into each chick. Another group of 12 chicks received only the pathogenic E. coli cells, which served as a negative control. Prophylactic action of the vaccines was evaluated on the basis of the number of survivals on the seventh day after infection, and survival rates were statistically analyzed using ⁇ 2 test. The results are shown below in Table 1.
- the table shows that the vaccines of the invention exhibit remarkable prophylactic action when compared with the conventional vaccines.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61-191119 | 1986-08-13 | ||
| JP61191119A JPH085802B2 (ja) | 1986-08-13 | 1986-08-13 | 家禽大腸菌症ワクチン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4837018A true US4837018A (en) | 1989-06-06 |
Family
ID=16269180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/079,803 Expired - Fee Related US4837018A (en) | 1986-08-13 | 1987-07-31 | Vaccines for fowl colibacillosis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4837018A (de) |
| EP (1) | EP0256792B1 (de) |
| JP (1) | JPH085802B2 (de) |
| KR (1) | KR960003606B1 (de) |
| AT (1) | ATE101044T1 (de) |
| AU (1) | AU597709B2 (de) |
| CA (1) | CA1306193C (de) |
| DE (1) | DE3788986D1 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688682A (en) * | 1992-04-27 | 1997-11-18 | Board Of Trustees Operating Michigan State University | Method for producing a bacterial vaccine and novel vaccines produced thereby |
| WO2004103402A1 (en) * | 2003-05-14 | 2004-12-02 | Wyeth | Avian e. coli vaccine for the protection against colibacillosis |
| US20070231346A1 (en) * | 2006-03-29 | 2007-10-04 | Babaev Eilaz P | Apparatus and methods for vaccine development using ultrasound technology |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4935761B2 (ja) * | 2008-06-02 | 2012-05-23 | 株式会社微生物化学研究所 | 家禽大腸菌症ワクチン |
| KR101321501B1 (ko) * | 2011-09-21 | 2013-10-29 | 주식회사 바이오포아 | 조류 대장균증 백신 조성물 및 이의 제조방법 |
| FR3145866A1 (fr) | 2023-02-16 | 2024-08-23 | Vaxinano | Composition vaccinale comprenant un systeme de delivrance d’une bacterie entiere inactivee via des nanoparticules cationiques |
| AU2024220779A1 (en) | 2023-02-16 | 2025-09-04 | Vaxinano | Vaccine composition comprising a system for delivering an inactivated whole bacterium via cationic polysaccharide nanoparticles without any adjuvant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4298597A (en) * | 1979-09-04 | 1981-11-03 | University Of Saskatchewan | Vaccine for diarrhea caused by E. coli |
| JPS58131920A (ja) * | 1982-01-29 | 1983-08-06 | Nisshin Flour Milling Co Ltd | 鶏の大腸菌症の予防法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3445568A (en) * | 1965-02-02 | 1969-05-20 | Gen Electric | Electrohydraulic process for producing antigens |
| US3558066A (en) * | 1969-01-21 | 1971-01-26 | Howard Alliger | Ultrasonic extraction of viable antigens from gram positive bacteria |
-
1986
- 1986-08-13 JP JP61191119A patent/JPH085802B2/ja not_active Expired - Fee Related
-
1987
- 1987-07-31 US US07/079,803 patent/US4837018A/en not_active Expired - Fee Related
- 1987-08-06 EP EP87306987A patent/EP0256792B1/de not_active Expired - Lifetime
- 1987-08-06 DE DE87306987T patent/DE3788986D1/de not_active Expired - Lifetime
- 1987-08-06 AT AT87306987T patent/ATE101044T1/de not_active IP Right Cessation
- 1987-08-12 AU AU76806/87A patent/AU597709B2/en not_active Ceased
- 1987-08-12 KR KR1019870008864A patent/KR960003606B1/ko not_active Expired - Lifetime
- 1987-08-12 CA CA000544351A patent/CA1306193C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4298597A (en) * | 1979-09-04 | 1981-11-03 | University Of Saskatchewan | Vaccine for diarrhea caused by E. coli |
| JPS58131920A (ja) * | 1982-01-29 | 1983-08-06 | Nisshin Flour Milling Co Ltd | 鶏の大腸菌症の予防法 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688682A (en) * | 1992-04-27 | 1997-11-18 | Board Of Trustees Operating Michigan State University | Method for producing a bacterial vaccine and novel vaccines produced thereby |
| WO2004103402A1 (en) * | 2003-05-14 | 2004-12-02 | Wyeth | Avian e. coli vaccine for the protection against colibacillosis |
| US7357935B2 (en) | 2003-05-14 | 2008-04-15 | Wyeth | Avian E. coli vaccine for protection against colibacillosis |
| CN100387299C (zh) * | 2003-05-14 | 2008-05-14 | 惠氏公司 | 用于预防大肠杆菌病的禽类大肠杆菌疫苗 |
| US20080213317A1 (en) * | 2003-05-14 | 2008-09-04 | Wyeth | Avian e. coli vaccine for protection against colibacillosis |
| US7575754B2 (en) | 2003-05-14 | 2009-08-18 | Wyeth | Avian E. coli vaccine for protection against colibacillosis |
| US20070231346A1 (en) * | 2006-03-29 | 2007-10-04 | Babaev Eilaz P | Apparatus and methods for vaccine development using ultrasound technology |
| US7842249B2 (en) | 2006-03-29 | 2010-11-30 | Bacoustics, Llc | Apparatus for vaccine development using ultrasound technology |
| US7943352B2 (en) | 2006-03-29 | 2011-05-17 | Bacoustics, Llc | Apparatus and methods for vaccine development using ultrasound technology |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE101044T1 (de) | 1994-02-15 |
| JPS6348224A (ja) | 1988-02-29 |
| EP0256792A2 (de) | 1988-02-24 |
| DE3788986D1 (de) | 1994-03-17 |
| CA1306193C (en) | 1992-08-11 |
| EP0256792B1 (de) | 1994-02-02 |
| AU7680687A (en) | 1988-02-18 |
| AU597709B2 (en) | 1990-06-07 |
| KR880002998A (ko) | 1988-05-13 |
| KR960003606B1 (ko) | 1996-03-20 |
| JPH085802B2 (ja) | 1996-01-24 |
| EP0256792A3 (en) | 1988-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0020356B1 (de) | Impfstoffe gegen pasteurellose | |
| Heddleston et al. | Fowl cholera: cross-immunity induced in turkeys with formalin-killed in-vivo-propagated Pasteurella multocida | |
| Anjum | Experimental transmission of hydropericardium syndrome and protection against it in commercial broiler chickens | |
| Deb et al. | Laboratory trials with inactivated vaccines against Escherichia coli (O78 K80) infection in fowls | |
| HU183765B (en) | Process for producing lyophilized vaccine against duck hepatitis | |
| US3876763A (en) | Infectious coryza infectious bronchitis and newcastle disease vaccines and production thereof | |
| US4302444A (en) | Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines | |
| US4837018A (en) | Vaccines for fowl colibacillosis | |
| US2912361A (en) | Canine distemper vaccine and its preparation | |
| EP0592454B1 (de) | Impfstofferzeugung | |
| Kogut et al. | Evaluation of Salmonella enteritidis‐immune lymphokines on host resistance to Salmonella enterica ser. gallinarum infection in broiler chicks | |
| JP2011506577A (ja) | 魚類ワクチン | |
| Rimler et al. | A growth medium for the production of a bacterin for immunization against infectious coryza | |
| Harry et al. | Laboratory and field trials on a formalin inactivated vaccine for the control of Pasteurella anatipestifer septicaemia in ducks | |
| US4746613A (en) | Poultry diseases bacterin preparation | |
| JPH09154572A (ja) | 弱毒性ニューカッスル病ウイルスワクチン | |
| EP1387693B1 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| HU210344A9 (en) | Cell free mareks disease virus vaccine | |
| US5069902A (en) | Virus and vaccine therefrom for use against turkey rhinotracheitis | |
| US3548054A (en) | Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease | |
| Montgomery et al. | Observations on the pathogenicity of Alcaligenes faecalis in chickens | |
| US4136169A (en) | Cross-protective fowl cholera bacterins | |
| US2998349A (en) | Vaccine against avian respiratory infection | |
| Boycott et al. | Experimental coryza in broiler chickens. I. Effects of vaccination with Haemophilus gallinarum bacterin and its components on weight gains and resistance to infection | |
| GB2029219A (en) | Pasteurellosis vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SHIONOGI & CO., LTD., NO. 12, 3-CHOME, DOSHO-MACHI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KONISHI, TAKAO;SUGIMORI, GIICHI;KATO, KAZUYOSHI;AND OTHERS;REEL/FRAME:004749/0810 Effective date: 19870713 Owner name: NISSHIN FLOUR MILLING CO., LTD., NO. 19-12, NIHONB Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KONISHI, TAKAO;SUGIMORI, GIICHI;KATO, KAZUYOSHI;AND OTHERS;REEL/FRAME:004749/0810 Effective date: 19870713 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| AS | Assignment |
Owner name: NISSHIN FLOUR MILLING CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SHIONOGI & CO., LTD;REEL/FRAME:006137/0776 Effective date: 19920423 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20010606 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |